INTRODUCTION: Nitrosation of nicotine or its metabolites in the human body could lead to formation of the 2 carcinogenic tobacco-specific nitrosamines-N'-nitrosonornicotine (NNN) and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK). METHODS: We investigated the possibility of endogenous formation of NNN in people who had stopped smoking and used the 21-mg nicotine patch for 6 months. We quantified urinary biomarkers of exposure to NNN-the sum of NNN and its pyridine-N-glucuronide, referred to as total NNN. Also measured were NNK metabolites-the sum of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) and its N- and O-glucuronides, referred to as total NNAL. RESULTS: The average decline of urinary total NNN was less drastic than that of total NNAL: 22% of baseline total NNN and 7.3% of baseline total NNAL were detected in urine 24 weeks after smoking cessation and patch use (p = .02). The average ratio of total NNN to total NNAL in the same urine samples increased from 0.14 in baseline urine to 0.38 after 24 weeks of nicotine patch use. DISCUSSION: Overall, these results demonstrate that endogenous formation of NNN may occur in nicotine patch users. However, the levels of urinary total NNN during patch use were generally extremely low. Moreover, in 10 of 20 subjects analyzed here, the rate of decline in total NNN was similar to that in total NNAL, indicating that endogenous formation of NNN is virtually nonexistent in these subjects. Supplementation with ascorbic acid could be a simple approach to block possible NNN formation in nicotine patch users.
INTRODUCTION: Nitrosation of nicotine or its metabolites in the human body could lead to formation of the 2 carcinogenictobacco-specific nitrosamines-N'-nitrosonornicotine (NNN) and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK). METHODS: We investigated the possibility of endogenous formation of NNN in people who had stopped smoking and used the 21-mg nicotine patch for 6 months. We quantified urinary biomarkers of exposure to NNN-the sum of NNN and its pyridine-N-glucuronide, referred to as total NNN. Also measured were NNK metabolites-the sum of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) and its N- and O-glucuronides, referred to as total NNAL. RESULTS: The average decline of urinary total NNN was less drastic than that of total NNAL: 22% of baseline total NNN and 7.3% of baseline total NNAL were detected in urine 24 weeks after smoking cessation and patch use (p = .02). The average ratio of total NNN to total NNAL in the same urine samples increased from 0.14 in baseline urine to 0.38 after 24 weeks of nicotine patch use. DISCUSSION: Overall, these results demonstrate that endogenous formation of NNN may occur in nicotine patch users. However, the levels of urinary total NNN during patch use were generally extremely low. Moreover, in 10 of 20 subjects analyzed here, the rate of decline in total NNN was similar to that in total NNAL, indicating that endogenous formation of NNN is virtually nonexistent in these subjects. Supplementation with ascorbic acid could be a simple approach to block possible NNN formation in nicotine patch users.
Authors: Cindy M Chang; Selvin H Edwards; Aarthi Arab; Arseima Y Del Valle-Pinero; Ling Yang; Dorothy K Hatsukami Journal: Cancer Epidemiol Biomarkers Prev Date: 2016-11-09 Impact factor: 4.254
Authors: Irina Stepanov; Steven G Carmella; Anna Briggs; Louise Hertsgaard; Bruce Lindgren; Dorothy Hatsukami; Stephen S Hecht Journal: Cancer Res Date: 2009-10-20 Impact factor: 12.701
Authors: Jean-François Etter; Chris Bullen; Andreas D Flouris; Murray Laugesen; Thomas Eissenberg Journal: Tob Control Date: 2011-03-17 Impact factor: 7.552
Authors: Delshanee Kotandeniya; Steven G Carmella; Makenzie E Pillsbury; Stephen S Hecht Journal: J Chromatogr B Analyt Technol Biomed Life Sci Date: 2015-10-31 Impact factor: 3.205
Authors: Aleksandar Knezevich; John Muzic; Dorothy K Hatsukami; Stephen S Hecht; Irina Stepanov Journal: Nicotine Tob Res Date: 2012-08-24 Impact factor: 4.244